Building on the growing body of research supporting collagen peptides for joint health, a new study suggests Peptan collagen peptides from Rousselot (Son, The Netherlands) may reduce joint inflammation and support cartilage regeneration in mice with osteoarthritis.
Researchers at the University of Rochester (Rochester, NY) studied the joint-health effects of Peptan administration on mice that were given either low-dosage Peptan (3.8mg/kg body weight), high-dosage Peptan (38 mg/kg body weight), or an empty control. After five weeks of supplementation, researchers induced post-traumatic osteoarthritis by injuring the meniscus and medial collateral ligament in the right knee of the mice. Joint biology was then assessed at three weeks and twelve weeks following the induction of osteoarthritis (considered early- and mid-stage disease, respectively).
In the Peptan groups, researchers observed visible tibial cartilage regeneration, dose-dependent preservation of cartilage, and regeneration of the extracellular matrix stimulating the production of proteoglycans—matrix components essential in lubrication of the joint, according to Rousselot.
“Peptan simultaneously supports all the connective tissues by stimulating local cells in the body to increase the production of collagen and other key matrix components,” said Mai Nygaard, global director for Peptan, Rousselot. “This new study adds to the growing body of literature testifying Peptan’s ability to support body mobility and joint health and will further strengthen its role in the supplements market.”
In addition, collagen peptides appeared to reduce joint inflammation, one of the main causes of joint pain. There was a significant reduction in the thickening of the synovial membrane that surround the knee in the Peptan groups, which is “a common symptom of joint inflammation during osteoarthritis development,” according to Rousselot. Compared to the control group, the Peptan-treated animals also showed significantly lower levels of TNF, a protein signaling inflammation, in the synovial membrane at both early- and mid-stage disease.
“This new study represents a strong basis to explain the data already published on symptom relief, and provides evidence that Peptan is a chondro-regenerative and anti-inflammatory in the context of post-traumatic knee osteoarthritis,” says Michael Zuscik, PhD, study author and associate professor of orthopaedics at Rochester University. “The results are extremely promising and can open up new doors to the potential benefits that collagen peptides can bring to joint health.”
Nutritional Outlook Magazine
Dar QA et al., “Oral hydrolyzed type 1 collagen induces chondroregenaration and inhibits synovial inflammation in murine posttraumatic osteoarthritis,” Osteoarthritis and Cartilage, vol. 24, suppl. 1 (April 2016): S532–S533